Update in nephrology and hypertension

Annals of Internal Medicine

Volumn 144, Issue 4, 2006, Pages 281-285

  Kimmel, Paul L ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IOPAMIDOL; SODIUM CHLORIDE; SPIRONOLACTONE; TRANDOLAPRIL; VERAPAMIL;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; METABOLIC SYNDROME X; MICROALBUMINURIA; NEPHROLOGIST; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; KIDNEY DISEASE;

CHRONIC DISEASE; CONTRAST MEDIA; DIABETIC NEPHROPATHIES; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X;

EID: 33644884989     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-4-200602210-00010     Document Type: Review

References (23)

1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-6.
2. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J. 2004;148:230-42.
3. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004;44:198-206.
4. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.
5. Hostetter TH. Chronic kidney disease predicts cardiovascular disease [Editorial]. N Engl J Med. 2004;351:1344-6.
6. National Kidney Disease Education Program. Health professionals MDRD calculator for adults. Accessed at http://nkdep.nih.gov/professionals/ gfr_calculators/mdrd.htm on 3 January 2006.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
8. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
9. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-9.
10. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.
12. Cook DJ, Guyatt GH. Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy [Editorial]. Ann Intern Med. 1999;131:707-8.
13. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660-7.
14. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-9.
15. Mitch WE. Treating diabetic nephropathy - are there only economic issues? N Engl J Med. 2004;351:1934-6.
16. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-61.
17. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
18. Jarman PR, Mather HM. Diabetes may be independent risk factor for hyperkalaemia [Letter]. BMJ. 2003;327:812.
19. Ghali WA, Cornuz J. Early uptake of research findings after fast-track publication [Letter]. Lancet. 2000;355:579-80.
20. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-4.
21. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
22. Briguori C, Tavano D, Colombo A. Contrast agent - associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503.
23. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2:38.